Loading
Life sciences · Journal article
npj Drug Discovery. · October 26, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
The cannabinoid receptor type 1 (CB 1 R), a G protein-coupled receptor within the endocannabinoid system, has been implicated in oncogenic signaling and cancer progression. Here, we developed a series of compact covalent molecular glue degraders designed to reduce CB 1 R abundance by recruiting components of the ubiquitin-proteasome system. Using rimonabant as a CB 1 R-binding scaffold, we generated small molecules incorporating electrophilic E3 ligase-recruiting handles and identified MG-CB2 as the most active degrader. MG-CB2 induced concentration- and time-dependent depletion of CB 1 R in MCF-7 breast cancer and HepG2 hepatocellular carcinoma cells. Proteasome inhibition blocked MG-CB2-mediated CB 1 R loss, while RNF126 knockdown abrogated degradation, supporting a proteasome- and RNF126-dependent mechanism. Rimonabant competition and cellular thermal shift experiments further supported cellular engagement of CB 1 R by MG-CB2. CB 1 R degradation was accompanied by modulation of CB 1 R-associated signaling, including reduced phosphorylation of ERK and mTOR and decreased BCL2 expression, along with reduced cancer-cell viability and migration. These findings establish covalent molecular glue-mediated degradation as a strategy for modulating CB 1 R abundance and signaling and expand the application of targeted protein degradation to a transmembrane GPCR.